Linagliptin

By
Created
Description
Quoth Wikipedia ever more:

Linagliptin (INN, previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2.

Once-daily linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type 2 diabetes. It is being marketed by Boehringer Ingelheim and Lilly.

Linagliptin may cause severe joint pain.
Tags
, , , , , , , , , , , , ,
Viewed by
225 People
Loved by
0 People
Filesize
4825 bytes